FirstFarms A/S
FirstFarms A/S adjusts the expectation for the year downwards due to Foot and Mouth Disease in Slovakia
FirstFarms A/S adjusts the expectation for the year downwards due to Foot and Mouth Disease in Slovakia
The Slovak authorities have yesterday 30 March 2025 confirmed an outbreak of Foot and Mouth Disease (FMD) in a livestock of 3,487 animals on FirstFarms’ farm in Plavecký Stvrtok, Slovakia.
Due to the outbreak at the cattle farm, FirstFarms adjusts downwards the announced expectations for 2025 with 45 mDKK to an EBITDA in the level of 70-110 mDKK and an EBIT of 0-40 mDKK.
The downward adjustment does not take into account any regional, national or EU support schemes in connection with FMD.
Announced expectations 2025 | EBITDA | EBIT |
31 March 2025 (company announcement no. 17) | 70-110 mDK | 0-40 mDKK |
13 March 2025 (company announcement no. 11) | 115-155 mDKK | 45-85 mDK |
Best regards,
FirstFarms A/S
For further information
Contact CEO Anders H. Nørgaard on phone +45 30 34 90 76.
About FirstFarms:
FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day, we work on creating a more sustainable company.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Gluco Tonic2.4.2025 04:46:19 CEST | Press release
GlucoTonic Reviews (DOCTOR INVESTIGATED): Is This Blood Sugar Breakthrough the Real Deal or Dangerous Hype
ProvaDent2.4.2025 03:18:11 CEST | Press release
ProvaDent Reviews (DENTIST INVESTIGATED): Can This Oral Probiotic Really Strengthen Teeth and Reverse Years of Damage?
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom